Keith A. Goldan
CIK: 0001495411
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Jun 1, 2026SNDX
Syndax Pharmaceuticals Inc
Sale(S)Direct1.2K shares at avg. $18.99$22K - Apr 1, 2026ABEO
ABEONA THERAPEUTICS INC.
Award(A)Direct32.8K shares- - Feb 9, 2026SNDX
Syndax Pharmaceuticals Inc
Sale(S)Direct3.4K shares at avg. $21.03$72K - Feb 6, 2026SNDX
Syndax Pharmaceuticals Inc
Sale(S)Direct2.1K shares at avg. $20.62$43K - Feb 4, 2026SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct21.5K shares- - Feb 4, 2026SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct30.8K shares- - Jan 30, 2026SNDX
Syndax Pharmaceuticals Inc
Other(J)Direct1.2K shares at avg. $8.48$10K - Dec 1, 2025SNDX
Syndax Pharmaceuticals Inc
Gift(G)Direct1.2K shares- - Jul 31, 2025SNDX
Syndax Pharmaceuticals Inc
Other(J)Direct1.2K shares at avg. $8.43$10K - Jul 16, 2025SNDX
Syndax Pharmaceuticals Inc
Sale(S)Direct1.3K shares at avg. $9.29$12K - May 19, 2025SNDX
Syndax Pharmaceuticals Inc
Purchase(P)Direct3K shares- - Feb 10, 2025SNDX
Syndax Pharmaceuticals Inc
Sale(S)Direct3.8K shares at avg. $15.50$59K - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct23.4K shares- - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct18.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 1, 2026 |  SNDX Syndax Pharmaceuticals Inc | Sale(S) | 1,177 | $18.99 | $22,351 | Direct |
| Apr 1, 2026 |  ABEO ABEONA THERAPEUTICS INC. | Award(A) | 32,751 | - | $0 | Direct |
| Feb 9, 2026 | SNDX Syndax Pharmaceuticals Inc | Sale(S) | 3,410 | $21.03 | $71,705 | Direct |
| Feb 6, 2026 | SNDX Syndax Pharmaceuticals Inc | Sale(S) | 2,082 | $20.62 | $42,931 | Direct |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 21,500 | - | $0 | Direct |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 30,750 | - | $0 | Direct |
| Jan 30, 2026 | SNDX Syndax Pharmaceuticals Inc | Other(J) | 1,219 | $8.48 | $10,337 | Direct |
| Dec 1, 2025 | SNDX Syndax Pharmaceuticals Inc | Gift(G) | 1,224 | - | - | Direct |
| Jul 31, 2025 | SNDX Syndax Pharmaceuticals Inc | Other(J) | 1,226 | $8.43 | $10,335 | Direct |
| Jul 16, 2025 | SNDX Syndax Pharmaceuticals Inc | Sale(S) | 1,296 | $9.29 | $12,033 | Direct |
| May 19, 2025 | SNDX Syndax Pharmaceuticals Inc | Purchase(P) | 3,000 | - | - | Direct |
| Feb 10, 2025 | SNDX Syndax Pharmaceuticals Inc | Sale(S) | 3,777 | $15.50 | $58,559 | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 23,400 | - | - | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 18,500 | - | - | Direct |
1-14 of 14 transactions
About Goldan Keith A.
Goldan Keith A. (SEC CIK 0001495411) files insider reports with the SEC as Chief Financial Officer of Syndax Pharmaceuticals Inc (SNDX) and Director of ABEONA THERAPEUTICS INC. (ABEO).
Signal8 holds 11 ownership filings by Goldan Keith A. (1 Form 3, 10 Form 4), filed between Feb 7, 2025 and Jun 2, 2026. Those filings report 14 transactions, from Feb 5, 2025 to Jun 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Goldan Keith A.'s filings is in NEW YORK, NY.
Recent filings by Goldan Keith A.
- Jun 1, 2026: Open-market sale of SNDX shares (Form 4, code S).
- Apr 1, 2026: Grant or award of ABEO shares (Form 4, code A).
- Feb 9, 2026: Open-market sale of SNDX shares (Form 4, code S).
- Feb 6, 2026: Open-market sale of SNDX shares (Form 4, code S).
- Feb 4, 2026: Grants or awards of SNDX shares (2 lines, Form 4, code A).
Other insiders filing for Syndax Pharmaceuticals Inc (SNDX)
- Podlesak Dennis, Director
- Metzger Michael A, Chief Executive Officer
- Botwood Nicholas A.J., Head of R&D, CMO
- Jarrett Jennifer, Director
- Huber Martin H. Jr., Director
- Rizo Aleksandra, Director